OncoSec Medical

OncoSec Medical

Employees:
50
Market Cap:
$21.91 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.29 million
NASDAQ:
ONCS

OncoSec Medical

Employees:
50
Market Cap:
$21.91 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.29 million
NASDAQ:
ONCS

Aug 28, 4:43 PM

Were proud of the progress weve made to advance OncoSecs science and technology. Check out our past scientific posters and presentations at http://bit.ly/1KKQHcq

Aug 24, 5:21 PM

Enjoy the last few weeks of summer, but remember to protect yourself and loved ones from the sun with these tips! #SummerSunSafetyMonth

Aug 15, 6:12 PM

Could an abundance of certain white blood cells present in tumors be the answer to predicting a patients response to immunotherapy in melanoma? Take a look at our latest blog post to learn more, http://oncosec.com/blog/

Jul 27, 8:41 PM

Anti-PD-1 refractory melanoma is a major unmet medical need. There are currently no available treatment options for patients with metastatic melanoma who have failed anti-PD-1 therapy. OncoSecs immunotherapy is in a position to be the first available treatment to this population.